The discovery and clinical development of new drugs—particularly therapies for kidney diseases—is a lengthy and costly process. Here, the authors discuss the need for closer collaboration between academia, industry and regulatory authorities to enable novel, efficient strategies for preclinical and clinical drug development. They also describe the current Japanese framework implemented to facilitate such collaboration.
- Toshio Miyata
- Tsuyoshi Ando
- Masahiro Takeuchi
